Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2020

01-04-2020 | Acute Myeloid Leukemia | Correspondence

Cannibalistic Hemophagocytosis in Acute Myeloid Leukemia with Trisomy 9

Authors: Somanath Padhi, Shruti Mishra, Gaurav Chhabra, Ashutosh Panigrahi

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2020

Login to get access

Excerpt

A 45-year-old male patient was subjective to bone marrow examination for evaluation of 10-day history of increasing fatigue secondary to severe anemia requiring packed red cell transfusion. His complete blood count at the time of admission revealed severe pancytopenia [hemoglobin-77 g/L, mean corpuscular volume-97 fL, total leukocyte count-0.8 × 109/L, and total platelet count-27 × 109/L, reticulocyte count-0.4 × 109/L]. Peripheral smear examination showed macrocytic normochromic red cells, 3% myeloid blasts with sparse, fine granules, no Auer rods; severe thrombocytopenia; and no evidence of pseudo Pelger Huet type neutrophils. His serum iron profile, vitamin B12, and folate levels were within normal reference range. Bone marrow aspiration from right posterior iliac crest revealed hypercellularity with infiltration by 75% myeloid blasts suppressing trilineage haematopoiesis. These blasts showed abundant pale basophilic finely vacuolated cytoplasm, few with sparse marginated granules and short slender Auer rod, few showing cytoplasmic blebs and pseudopod like extensions; round nuclei, fine chromatin and conspicuous nucleoli. Maturing myeloid elements constituted 10% of marrow nucleated cells. Ten percent of blasts had evidence of hemophagocytic activity of RBCs, platelets, and myeloid cells. Besides these, 3% of these blasts also showed engulfment of another blasts (cannibalism) (Fig. 1a–c). Flow cytometry immunophenotyping of the marrow aspirate using BD FACS Canto II flow cytometer (Becton–Dickinson, San Jose, CA, USA) revealed the following blast profile: SSClow/CD45+/dim, CD34+/bright, HLADR+/bright, CD13+/moderate, CD33+/bright, CD117+/bright, and aberrant CD7+/bright; but negative for cMPO, CD 14, CD 64, cCD 79a, CD 19, and cCD 3; consistent with a diagnosis of MPO negative acute myeloid leukemia (AML) (Fig. 2). Bone marrow trephine biopsy showed the infiltration by diffuse sheets of CD34+/CD117+/MPO/CD31+/Glycophorin/CD61 myeloid blasts with evidence of hemophagocytosis and increased reticulin fibrosis (WHO grade 2). Conventional G-banding cytogenetics from the marrow aspirate sample revealed trisomy 9 as the sole abnormality in 9 of 20 analyzed metaphases (47, XY, + 9 [5]/46, XY [15]) (Fig. 3). His molecular work up did not show any abnormality; and his serum ferritin and fasting triglyceride levels were within normal limits. The patient refused induction chemotherapy; and subsequently lost to follow-up. The next of the kin of the patient gave verbal informed consent to write up the case.
Literature
1.
go back to reference Imashuku S, Hibi S, Sako M, Lin Y-W, Ikuta K, Nakata Y et al (2000) Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t (16; 21) (p11; q22): common morphologic characteristics for this type of leukemia. Cancer 88:1970–1975CrossRef Imashuku S, Hibi S, Sako M, Lin Y-W, Ikuta K, Nakata Y et al (2000) Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t (16; 21) (p11; q22): common morphologic characteristics for this type of leukemia. Cancer 88:1970–1975CrossRef
2.
go back to reference Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM et al (2009) AML with translocation t (8; 16) (p11; p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23:934–943CrossRef Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM et al (2009) AML with translocation t (8; 16) (p11; p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23:934–943CrossRef
3.
go back to reference Jekarl DW, Kim M, Lim J, Kim Y, Han K, Lee A-W et al (2010) CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t (16; 21) (p11; q22). Int J Hematol 92:306–313CrossRef Jekarl DW, Kim M, Lim J, Kim Y, Han K, Lee A-W et al (2010) CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t (16; 21) (p11; q22). Int J Hematol 92:306–313CrossRef
4.
go back to reference Wang E, Maggie Stoecker M (2010) “Cannibalistic” phagocytosis in acute megakaryoblastic leukemia (AML M7) with t (10; 17) (p15; q22). Leukemia Lymphoma 51:1944–1947CrossRef Wang E, Maggie Stoecker M (2010) “Cannibalistic” phagocytosis in acute megakaryoblastic leukemia (AML M7) with t (10; 17) (p15; q22). Leukemia Lymphoma 51:1944–1947CrossRef
5.
go back to reference Li L, Zhou F, Hou J (2012) Acute myeloid leukemia with t (10; 17) (p13; q12) chromosome translocation: a case report and literature review. Am J Blood Res 2:265–268PubMedPubMedCentral Li L, Zhou F, Hou J (2012) Acute myeloid leukemia with t (10; 17) (p13; q12) chromosome translocation: a case report and literature review. Am J Blood Res 2:265–268PubMedPubMedCentral
6.
go back to reference Wiseman DH, Bonney DK, Wynn RF (2012) Hemophagocytosis by leukemic megakaryoblasts in acute myeloid leukemia (megakaryoblastic) with t (1; 22) (p13; q13); RBM15-MKL1. J Pediatr Hematol Oncol 34:576–580CrossRef Wiseman DH, Bonney DK, Wynn RF (2012) Hemophagocytosis by leukemic megakaryoblasts in acute myeloid leukemia (megakaryoblastic) with t (1; 22) (p13; q13); RBM15-MKL1. J Pediatr Hematol Oncol 34:576–580CrossRef
7.
go back to reference Hatano K, Nagai T, Matsuyama T, Sakaguchi Y, Fujiwara S, Oh L et al (2015) Leukemic cells directly phagocytose blood cells in AML-associated hemophagocytic lymphohistiocytosis: a case report and review of the literature. Acta Hematol 133:98–100CrossRef Hatano K, Nagai T, Matsuyama T, Sakaguchi Y, Fujiwara S, Oh L et al (2015) Leukemic cells directly phagocytose blood cells in AML-associated hemophagocytic lymphohistiocytosis: a case report and review of the literature. Acta Hematol 133:98–100CrossRef
8.
go back to reference Andrade FG, Noronha EP, Baseggio RM, Fonseca TCC, Freire BMR, Magalhaes IMQ et al (2016) Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. Rev Bras Hematol Hemoter 38:291–297CrossRef Andrade FG, Noronha EP, Baseggio RM, Fonseca TCC, Freire BMR, Magalhaes IMQ et al (2016) Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. Rev Bras Hematol Hemoter 38:291–297CrossRef
11.
go back to reference Shobhanaa PS, Kakkar N (2018) Cannibalism in relapsed B-acute lymphoblastic leukemia. Indian J Hematol Blood Transfus 34:544–545CrossRef Shobhanaa PS, Kakkar N (2018) Cannibalism in relapsed B-acute lymphoblastic leukemia. Indian J Hematol Blood Transfus 34:544–545CrossRef
12.
go back to reference Chaubey R, Sazawal S, Dada R, Sharma P, Pathak D, Saxena R (2010) Trisomy 9 in a patient with acute myelogenous leukaemia FAB type M2: a rare occurrence. Indian J Hematol Blood Transfus 26:103–105CrossRef Chaubey R, Sazawal S, Dada R, Sharma P, Pathak D, Saxena R (2010) Trisomy 9 in a patient with acute myelogenous leukaemia FAB type M2: a rare occurrence. Indian J Hematol Blood Transfus 26:103–105CrossRef
Metadata
Title
Cannibalistic Hemophagocytosis in Acute Myeloid Leukemia with Trisomy 9
Authors
Somanath Padhi
Shruti Mishra
Gaurav Chhabra
Ashutosh Panigrahi
Publication date
01-04-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01223-5

Other articles of this Issue 2/2020

Indian Journal of Hematology and Blood Transfusion 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine